Skip to main content

Advertisement

SpringerLink
Log in

Patent watch

Migraine therapies targeting the CGRP pathway: intellectual property landscape

  • Biobusiness Briefs
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Intellectual property landscape for CGRP pathway antagonists.

Author information

Authors and Affiliations

  1. Global Prior Art, Inc., 21 Milk Street, Boston, 02109, Massachusetts, USA

    Jeannette L. A. Fiala & Drew Lowery

Authors
  1. Jeannette L. A. Fiala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Drew Lowery
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Drew Lowery.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information S1 (box)

Dataset and analysis methods (PDF 322 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fiala, J., Lowery, D. Migraine therapies targeting the CGRP pathway: intellectual property landscape. Nat Rev Drug Discov 15, 8–9 (2016). https://doi.org/10.1038/nrd.2015.11

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2015.11

  • Springer Nature Limited

Search

Navigation